Oct 21 (Reuters) – A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Thursday are considering several recommendations for rollout of COVID-19 vaccine boosters from Moderna Inc (MRNA.O) and Johnson & Johnson (JNJ.N), expected to pave the way for additional shots for millions of Americans.
The U.S. Food and Drug Administration on Wednesday authorized the booster doses, and said Americans can choose a different shot from their original inoculation.
The CDC is expected to sign off in the coming days on the recommendations of the panel for a booster rollout that health officials and public health experts said could be confusing.
“I think at the moment, it really is quite confusing,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center and a non-voting member of the CDC’s Advisory Committee on Immunization Practices.
Schaffner noted that there are several categories of eligibility just for the Pfizer booster doses, and the FDA just added two more vaccine boosters to the mix.
Click here to read more.